When: $1,050 (200 SMA) on weekly close support only

Then: Add max 1.5% NAV per tranche

HOLD at 2-3% with $1,050 stop-loss; trim discipline recommended

• Forward P/E of 26.4x with 59% implied EPS growth relies on aspirational sell-side estimates rather than realized earnings
• Trailing P/E of 41.9x and P/B of 32.8x represent actual market pricing—investors paying 32.8x book value assumes future is guaranteed
• PEG of 1.58 is thin margin for a trillion-dollar pharma facing patent clock risks
• MACD has decayed from 44 (mid-June peak) to 21.81, not healthy consolidation but momentum deterioration
• ATR expanded 39% in three months; volatility at highest level in the entire run
• Proposed stop at $1,050 represents 16% drawdown; with beta of 0.51, drawdown risk is 3-4x what defensive portfolio should tolerate on single position
• Polymarket pricing only 3% probability for retatrutide approval in 2026; next major catalyst 12-18 months away
• Net debt rose from $35 billion to $46 billion in roughly six months
• CapEx nearly doubled year-over-year, indicating heavy capital deployment without corresponding near-term returns
• 86% probability priced for zero Fed rate cuts in 2026 is headwind for high-multiple growth names
• Rising geopolitical uncertainty keeping volatility elevated
• GLP-1 represents lion's share of growth narrative—single-mechanism concentration risk
• Market already priced UK oral GLP-1 launch, diagnostic clearance, and smart-money accumulation at $1.1T valuation

→ vs aggressive: Forward EPS estimates used to justify valuation are aspirations, not earnings; anchoring risk assessment to these numbers loses margin of safety

→ vs aggressive: MACD at 21.81 vs prior peak of 44 is momentum decay, not healthy consolidation as claimed

→ vs aggressive: ATR expanded 39% in three months with highest volatility in the run—adding risk when risk-to-reward is deteriorating

→ vs aggressive: Stock cooling from $1.1T market cap with positive news flow indicates market questioning whether next growth leg justifies multiple

→ vs aggressive: Sizing up beyond 2-3% is precisely wrong in high-ATR, high-multiple, macro-headwind environment

→ vs aggressive: The 3% Polymarket probability for retatrutide approval in 2026 means biggest near-term catalysts are largely already priced in

→ vs aggressive: Rising net debt and near-doubling CapEx without near-term catalysts increases balance sheet risk

HOLD at 2-3% cap; reject both aggressive sizing up and conservative trimming

• HOLD at 2-3% position cap is correct; neither aggressive nor conservative arguments should move this disposition
• Forward P/E of 26.4x is rich but sell-side estimates are directionally correct; magnitude may disappoint but trajectory is real
• Revenue growth of 47.7% YoY (Q2 2026) with ~$90B+ annualized revenue potential versus trailing ~$80B indicates earnings inflection underway
• Trailing P/E of 41.9x and P/B of 32.8x are stale/misleading metrics; intangibles jumped from $6.5B to $18.1B in one quarter from M&A
• Long-term trend is bullish but short-term momentum fading; MACD at 21.81 well below prior peaks of 40-44; ATR expanding 39% in three months
• Price 18.6% above 200 SMA with steepening 50 SMA and volume-weighted accumulation confirms structural uptrend intact
• 47.7% revenue growth concentrated in incretin mechanisms; Polymarket shows only 3% probability of retatrutide approval in 2026
• Beta of 0.51 makes LLY defensive within growth universe; macro headwind affects multiple but not earnings power
• 86% probability of zero Fed cuts is real headwind but 10% multiple compression (26x to 23x) with 50% earnings growth still produces positive return
• Tiered re-entry at $1,180, $1,100, $1,050 is opportunistic not mandatory; if LLY moves higher on catalysts first, that's acceptable cost
• Stop at $1,050 should be supplemented with structural warning at $1,180 weekly close below 50 SMA for earlier signal
• Position sizing ceiling remains 3% until Q3 earnings confirm 47% revenue growth trajectory sustainable or Foundayo UK data justifies TAM expansion
• Diversification is silent risk; LLY should not be largest single position regardless of conviction due to idiosyncratic shocks (patent rulings, FDA decisions, competitive entries)
• Conservative's implicit trim recommendation is overcorrection; position already at 2-3% cap means trimming addresses wrong position size

→ vs aggressive: Position sizing argument is weakest part of case; saying size up beyond 3% on single name with 47.7% revenue concentrated in incretin mechanisms is concentration risk masquerading as confidence; 3% probability of retatrutide approval in 2026 means pipeline story supporting higher multiple is largely back-loaded

→ vs aggressive: Closing line about not letting caution turn into inaction is a trap; caution protects gains on names like this; people who made most money on LLY held disciplined positions through volatility, not those who sized up aggressively at every pop

→ vs conservative: Trailing P/E argument is misleading by design; trailing P/E reflects yesterday's earnings which were substantially lower than today's run-rate; Q2 revenue grew 47.7% YoY so denominator is already stale

→ vs conservative: P/B argument deserves scrutiny; intangibles jumped from $6.5B to $18.1B in single quarter due to M&A which mechanically inflates P/B ratio

→ vs conservative: Implicit recommendation to trim is overcorrection; position already capped at 2-3% so trim argument addresses wrong position size; suggestion to sell at current levels to buy back at $1,180 is market-timing trade dressed as prudence

→ vs conservative: Macro point is most correct but applied incorrectly; beta of 0.51 makes LLY defensive by construction; zero cuts affects multiple compression risk but doesn't fundamentally impair earnings power